key: cord-0848327-lm5nmhqq
authors: King, C.; Lista-de Weever, E.; Henry, M.; Steingrover, R.; Fleming, C.; Panneflek, R.; van Kampen, S.
title: Validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) to screen for SARS-CoV-2 infection in Sint Maarten: a diagnostic accuracy study
date: 2021-09-24
journal: nan
DOI: 10.1101/2021.09.23.21260526
sha: e0538f84208805711d154624b29ae8c6919979d2
doc_id: 848327
cord_uid: lm5nmhqq

Objectives: Control of the pandemic has required countries to look for other forms of tests besides the gold standard real-time polymerase chain reaction (RT-PCR). Rapid antigen tests (RAT), though less sensitive than RT-PCR, offer the possibility of rapid, inexpensive and early detection of the most infectious COVID-19 cases. Only very few studies have assessed the performance of the Abbott Panbio COVID-19 RAT among asymptomatic people or in Latin America. This study set out to validate this test among people attending the public test street in Sint Maarten, Dutch Caribbean. Methods: People of all ages were recruited from the public COVID-19 test street regardless of COVID-19 symptoms. They received a nasopharyngeal swab for the Abbott Panbio COVID-19 RAT and the RT-PCR Qtower. Diagnostic accuracy of the RAT was compared to the RT-PCR among the overall study population and for subgroups with/without symptoms, with/without close contact and different Ct values. Results: Using a RT-PCR Ct cut-off value of <33, 119 out of 1,411 people (8.4%) tested positive for SARS-CoV-2. Most were asymptomatic (59%). The overall sensitivity and specificity of the RAT was 84% (95% CI 76.2-90.1) and 99.9% (95% CI 99.6-100) respectively. The sensitivity reduced to 67.6% (95% CI: 49.5%, 82.6%) among people without symptoms, regardless of whether they were in close contact with a known COVID-19 case. Sensitivity reduced considerably with a Ct cut-off value of <35. Conclusions: The Abbott Panbio RAT is a valid and cheaper alternative to RT-PCR when used on symptomatic individuals among the general population. However, among asymptomatic people it should not be used as a stand-alone test and negative results should be confirmed with RT-PCR.

Adequate and rapid diagnostics are essential for the treatment and control of COVID-19. 1 

The gold standard test to detect the SARS-CoV-2 virus is real-time polymerase chain reaction 55 (RT-PCR), a molecular assay targeting specific viral DNA. 2 In Sint Maarten, the public health 56 authorities use RT-PCR for SARS-CoV-2 testing to identify current infections in individuals 57 with signs or symptoms consistent with COVID-19. This testing is also used when an 58 asymptomatic person has been in contact with a SARS-CoV-2 positive case or identified by a 59 positive person through contact tracing. 60 61 While RT-PCR has optimal sensitivity and specificity to detect SARS-CoV-2, it is an 62 expensive technique that can only be performed in well-equipped laboratories with trained 63 laboratory staff. Control of the pandemic has required countries to look for other forms of 64 tests besides the standard RT-PCR. Rapid antigen tests (RAT), though less sensitive than RT-65 PCR, offer the possibility of rapid, inexpensive and early detection of the most infectious 66 COVID-19 cases in appropriate settings. 3 RATs generally use an immunological lateral flow 67 assay to detect SARS-CoV-2 viral antigens. 4 RATs would be an appropriate alternative to 68 RT-PCR for many settings considering it would reduce the pressure on laboratories, while 69 also expanding testing capacity. A recent study from the Netherlands and Aruba found that 70 the Abbott Panbio COVID-19 RAT had a sensitivity of 87.4% and a specificity of 100% 71 among symptomatic people. 5 Only very few studies have assessed the performance of the 72 Abbott Panbio COVID-19 RAT among asymptomatic people or in Latin America and the 73 Carribbean. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The study only collected personal data that was already routinely collected when people 120 attend the public health test street. 121 122 Participant characteristics were compared between people that tested positive and negative for 123 COVID-19 with RT-PCR. Differences in terms of age, sex, symptoms and close contact 124 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 24, 2021. ; https://doi.org/10.1101/2021.09.23.21260526 doi: medRxiv preprint were female (59%), asymptomatic (59%) and had had no close contact with someone with 150 COVID-19 (60%) ( Table 1) . Most commonly reported symptoms were headache (17%), cough 151 (17%), runny/stuffy nose (17%), and sore throat (15%). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint and half of the asymptomatic people had been in close contact with a COVID-19 positive 184 person. Compared to symptomatic people, the sensitivity was drastically lower among 185 asymptomatic people (67.6%) and below the minimally recommended sensitivity of 80% for a 186 RAT as recommended by WHO and far below the 90% as recommended by ECDC. 10 The 187 NPV among this group remained at 98.7% due to the low prevalence of COVID-19. Although 188 there were slight variations in the specificity for different subgroups, it always stayed above 189 the recommended 97%. 190

The 84% overall sensitivity of the Abbott Panbio COVID-19 RAT estimated in this study was 192 very similar to that found in studies using the same Ct cut-off value of <33. For example, two 193 prospective studies in community testing sites in Switzerland and Germany found similar 194 sensitivities of 89.7% and 88.3%, respectively. 11 Two studies in Spain that evaluated the 195 Abbott Panbio RAT in primary health care centers reported lower overall sensitivities of 196 71.4% and 79.6% respectively, which may be due to the higher Ct cut-off value used. 12 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 24, 2021. ; https://doi.org/10.1101/2021.09.23.21260526 doi: medRxiv preprint

Rapid, point-ofcare antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev

Considerations for diagnostic COVID-19 tests

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance

Ag Rapid Test Device | Abbott Point of Care Testing

COVID-19: hoe betrouwbaar zijn sneltesten?

Rapid antigen tests for the diagnosis of a SARS-CoV-2 infection

Advice on the use of point-of-care immunodiagnostic tests for

Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity

Current performance of COVID-19 test methods and devices and proposed performance criteria. Working document of Commission services

11 FIND Evaluation of Abbott Panbio COVID-19 Ag Rapid Test Device External Report Version 2.1

Evaluation of the Panbio™ rapid antigen test for SARS-CoV-2 in primary health care centers and test sites

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres

Antigen Rapid Test Validation Group. Screening for SARS-CoV-2 infection in asymptomatic individuals using the Panbio COVID-19 Antigen Rapid Test (Abbott) compared to RT-qPCR